FDA Approves Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors Based on Results from Alliance CABINET Trial

Today, the Alliance for Clinical Trials in Oncology was informed that the U.S. Food and Drug Administration has approved cabozantinib for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs). NETs are a type of cancer that manifest characteristics of both nerve and hormone-producing cells, and can arise in various parts of the body, most commonly in the gastrointestinal tract, lungs, or pancreas. NETs affect patients in very different ways, and only a few tr

• Read more